Related Experiment Videos
[Troxacitabine].
Henriette Gourdeau1, Jacques Jolivet
1Shire BioChem Inc., 275, boulevard Armand-Frappler, Québec, Canada, H7V 4A7. henriettegourdeau@videotron.com
Bulletin Du Cancer
|June 3, 2004
Summary
Troxacitabine, a novel nucleoside analogue with a unique stereochemical configuration, shows broad anticancer activity. Preclinical data and early clinical trials support its potential in treating hematological malignancies and solid tumors.
Area of Science:
- Oncology
- Medicinal Chemistry
- Pharmacology
Context:
- Nucleoside analogues are established antimetabolites in cancer therapy.
- These drugs interfere with DNA synthesis and induce apoptosis.
- Hematological malignancies and solid tumors remain significant therapeutic challenges.
Purpose:
- To present preclinical data and initial clinical trial findings for troxacitabine.
- To evaluate the anticancer potential of a novel nucleoside analogue.
- To summarize the safety and efficacy of troxacitabine in early-phase trials.
Summary:
- Troxacitabine is the first nucleoside analogue with an unnatural stereochemical configuration and anticancer activity.
- It exhibits a broad preclinical antineoplastic spectrum.
- Initial Phase I and II clinical trials are summarized, detailing its development.
Impact:
- Troxacitabine represents a novel therapeutic agent for cancer treatment.
- Its unique structure may offer advantages over existing nucleoside analogues.
- Further clinical investigation is warranted to establish its role in oncology practice.